Intérêt de la MGMT dans les gliomes. [MGMT analysis in gliomas]. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Bulletin du Cancer Year : 2011

Intérêt de la MGMT dans les gliomes. [MGMT analysis in gliomas].

Abstract

MGMT status is now regarded as a strong predictive factor of response to standard treatment of newly diagnosed glioblastomas involving temozolomide (TMZ) and radiotherapy. MGMT promoter methylation is also a prognostic factor - independent of treatment - in anaplastic gliomas. The predictive function can be explained by the role of the DNA repair enzyme MGMT, which antagonizes the effects of alkylating agents such as TMZ. MGMT promoter methylation could also reflect a particular molecular phenotype with its own specific prognostic significance. Since MGMT status determination is becoming a crucial biological marker in new clinical glioma trials, and is beginning to be used in day-to-day clinical practice, there is currently a strong need to determine the best technique for MGMT analysis. A French multicenter study has been set up for this purpose.

Domains

Cancer
No file

Dates and versions

inserm-00587564 , version 1 (20-04-2011)

Identifiers

Cite

Véronique Quillien, Elodie Vauléon, Stephan Saikali, Thierry Lesimple, Abderrahmane Hamlat, et al.. Intérêt de la MGMT dans les gliomes. [MGMT analysis in gliomas].. Bulletin du Cancer, 2011, 98 (3), pp.291-303. ⟨10.1684/bdc.2011.1332⟩. ⟨inserm-00587564⟩
137 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More